Renalytix AI plc (RENX) - Total Liabilities

Latest as of December 2024: GBX12.81 Million GBX ≈ $1.56K USD

Based on the latest financial reports, Renalytix AI plc (RENX) has total liabilities worth GBX12.81 Million GBX (≈ $1.56K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Renalytix AI plc growing its equity to track the company's year-over-year net asset growth rate.

Renalytix AI plc - Total Liabilities Trend (2012–2025)

This chart illustrates how Renalytix AI plc's total liabilities have evolved over time, based on quarterly financial data. See Renalytix AI plc (RENX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Renalytix AI plc Competitors by Total Liabilities

The table below lists competitors of Renalytix AI plc ranked by their total liabilities.

Company Country Total Liabilities
Empresaria Group plc
LSE:EMR
UK GBX75.60 Million
Meyer Burger Tech AG
SW:MBTN
Switzerland CHF545.59 Million
Kukbo Co. Ltd.
KO:001140
Korea ₩69.22 Billion
LANEBURY GROWTH CAP.
F:L01
Germany €7.23 Million
Prospex Energy PLC
LSE:PXEN
UK GBX992.70K
Vergnet
PA:ALVER
France €41.97 Million
Braime Group PLC
LSE:BMT
UK GBX15.15 Million
Lexington Gold Ltd
LSE:LEX
UK GBX593.00K

Liability Composition Analysis (2012–2025)

This chart breaks down Renalytix AI plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Renalytix AI plc (RENX) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.43 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -9.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.12 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Renalytix AI plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Renalytix AI plc (2012–2025)

The table below shows the annual total liabilities of Renalytix AI plc from 2012 to 2025.

Year Total Liabilities Change
2025-06-30 GBX13.10 Million
≈ $1.59K
-17.22%
2024-06-30 GBX15.83 Million
≈ $1.93K
-99.97%
2023-12-31 GBX54.50 Billion
≈ $6.63 Million
+230225.83%
2023-06-30 GBX23.66 Million
≈ $2.88K
+17.79%
2022-06-30 GBX20.09 Million
≈ $2.44K
+168.71%
2021-06-30 GBX7.48 Million
≈ $909.61
+40.10%
2020-06-30 GBX5.34 Million
≈ $649.24
+606.75%
2019-06-30 GBX755.00K
≈ $91.86
+1043.68%
2018-06-30 GBX66.02K
≈ $8.03
-100.00%
2016-12-31 GBX41.52 Billion
≈ $5.05 Million
+5.56%
2015-12-31 GBX39.33 Billion
≈ $4.79 Million
-3.76%
2014-12-31 GBX40.87 Billion
≈ $4.97 Million
-3.33%
2013-12-31 GBX42.28 Billion
≈ $5.14 Million
+6.03%
2012-12-31 GBX39.87 Billion
≈ $4.85 Million
--

About Renalytix AI plc

LSE:RENX UK Health Information Services
Market Cap
$148.88K
GBX1.22 Billion GBX
Market Cap Rank
#31256 Global
#1051 in UK
Share Price
GBX2.80
Change (1 day)
+5.66%
52-Week Range
GBX1.80 - GBX10.75
All Time High
GBX1220.00
About

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more